Confidential  Page 1 of 14 
 
  
 
 
 
Minimal Opioid Use After Total Hip Rep lacement 
(THR) : A Blinded , Randomized, Placebo -Controlled 
Study  
 
FUNDER : Anesthesiology  Department,  
Hospital f or Special Surgery  
PROTOCOL NO.:  2017 -0721  
DATE:  0625/2020  
 
 
 
 
 
 
 
 
 
 
 
 
This document contains the c onfidential information of the Hospital for Special Surgery.  It is provided to you and your company’s personnel for 
review.  Your acceptance of this document constitutes an agreement that you will not disclose the information contained herein to othe rs wi thout 
the prior written consent of the Hospital for Special Surgery.  No other use or reproduction is authorized by Hospital f or Special Surgery, nor does 
the Hospital for Special Surgery assume any responsibility for unauthorized use of this protocol.  
 
 

 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 2 of 14 
 
 TABLE OF CONTENTS   
TABLE OF CONTENTS ................................ ................................ ................................ ...................  2 
PROTOCOL SYNOPSIS ................................ ................................ ................................ ..................  3 
1.0     INTROD UCTION  ................................ ................................ ................................ ....................  4 
    2.0 PRODUCT DESCRIPTION………………… …….. ………………………………………………. 4 
3.0      OBJECTIVE OF CLINICAL STUDY  ................................ ................................ ......................  4 
4.0      STUDY HYPOTHESIS  ................................ ................................ ................................ ...........  4 
5.0      STUDY DESIGN  ................................ ................................ ................................ ....................  4 
5.1 Study Duration  ................................ ................................ ................................ ................  4 
5.2 Endpoints  ................................ ................................ ................................ .......................  4 
5.2.1 Primary Endpoint  ................................ ................................ ................................ ...... 4 
5.2.2 Secondary Endpoints  ................................ ................................ ................................  4 
5.2.3 Safety Evaluations.  ................................ ................................ ................................ ... 4 
5.3 Study Site  ................................ ................................ ................................ .......................  4 
6.0        STUDY POPULATION  ................................ ................................ ................................ .........  4 
6.1 Number of Subjects  ................................ ................................ ................................ ........  4 
6.2 Inclusion Criteria ................................ ................................ ................................ .............  5 
6.3 Exclusion Criteria:  ................................ ................................ ................................ ..........  5 
    6.4        Randomization……………………………………………………………………………… ..5 
7.0         PROCEDURES  ................................ ................................ ................................ ....................  5 
7.1 Surgical Procedure  ................................ ................................ ................................ .........  5 
 7.1.1. Investig ational Product Administration…… ………………………………………….  .…..5 
7.2 Imaging Procedure  ................................ ................................ ................................ .........  5 
7.3 Medical Record Requirements  ................................ ................................ .......................  5 
7.4 Data Collection  ................................ ................................ ................................ ...............  5 
    7.5        Schedu le of Assessments…………………………………………………… ..…………… .. 6 
7.6 Radiological Evaluations  ................................ ................................ ................................  7 
7.7 Clinical Evaluations  ................................ ................................ ................................ ........  7 
 7.7.1. Revision Surgery………………………………… ……………………………………. .…… 7 
8.0         STATISTICAL ANALYSIS  ................................ ................................ ................................ .. 7 
9.0         ADVERSE EVENT ASSESSMENT  ................................ ................................ .....................  7 
9.1 Adverse Event (AE)  ................................ ................................ ................................ ........  7 
9.2 Serious Adverse Events (SAE)  ................................ ................................ ......................  7 
9.3 Subsequent Surgical Interventions Definitions  ................................ ..............................  7 
9.4 Adverse Event Relationship  ................................ ................................ ...........................  7 
9.5 Adverse Event Recording  ................................ ................................ ..............................  7 
9.6 Adverse Event Reporti ng ................................ ................................ ...............................  7 
10.0         INVESTIGATOR RESPONSIBILITIES, RECORD AND REPORTS  ................................  7 
10.1 Subject Consent and Information  ................................ ................................ ...................  7 
10.2 Subject Data Protection  ................................ ................................ ................................ . 7 
10.3 Staff Information  ................................ ................................ ................................ .............  8 
10.4 Protocol Reviews ................................ ................................ ................................ ............  8 
10.5 Investigator Records  ................................ ................................ ................................ ...... 8 
10.6 Investigator Reports  ................................ ................................ ................................ ....... 8 
 11.0  REFERENCES ……………………………………………… ……………… .……………… ….8 
APPENDIX A: Case Report Forms  ................................ ................................ ..............................  9 
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 3 of 14 
 
 
PROTOCOL SYNOPSIS  
Protocol Title:  Minimal Opioid use after Total Hip Replacement (THR): a 
blinded randomized placebo -controlled study  
Protocol Number:  2017 -0721 
Protocol Date:  6/25/2020  
Sponsor:  Hospital for Special Surgery, Department of Anesthesiology  
Principal 
Investigator:  Kethy J ules-Elysee, MD  
Objective:  Total hip arthroplasty can be associated with significant 
postoperative pain. Side effects of pain management m ay impair 
participation in physical therapy and slow readiness for 
discharge from the hospital. In a previous study done by our 
group, epidural p atient -controlled analgesia (EPCA) with a 
hydromorphone containing solution appeared to have a more 
favorable p ain profile with ambulation, but greater side effects 
compared to injection of a peri -articular cocktail. The use of 
opioid was greater in the pe ri-articular injection group (PAI). 
There was no difference in length of stay. In view of the 
controversy over opioid use, we would like to develop an optimal 
opioid sparing pain management approach by comparing 3 
different protocols 1) Plain local anesthe tic EPCA; 2) PAI; 3) 
EPCA + PAI; all in conjunction with a multimodal opioid sparing 
pain regimen.  The goal wo uld be to maximize pain control while 
minimizing opioid use and side -effects . 
Study Design:  Randomized Controlled Clinical Tria l 
Enrollment:  180 total (60 in each group)  
Subject Criteria:  - Patients with osteoarthritis sch eduled for primary total 
hip arth roplasty with participating surgeon  
- Age 45 to 80 years old  
- Planned use of regional anesthesia  
- Ability to follow study protocol  
- Planned posterolateral surgical approach  
Study Duration:  Enrollment Period: Pre -op, intra -op, post -op (POD0 -3, 7, 90) ; 
Duration of Follow ups: Approximately 15 mins each  
Data Collection:  • Collected from medical records and patient.  
Outcome 
Parameters:  • Opioid use (oral morphine equivalents, cumulative, within 
24 hours).  
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 4 of 14 
 
1.0 INTRODUCTION  
Total hip arthroplasty can be associated with significant postoperative pain. Sid e effects of 
pain management may impair pa rticipation in physical therapy and slow  readiness fo r 
discharge from the hospital. In a previous study done by our group,  epidural patient 
controlled analgesia (EPCA) with a hydromorphone containing  solution appeared to have a 
more favorable pain profile with ambulation, but  greater side effects compared to injection of 
a peri -articular cocktail. The use of  opioid was greater in the peri -articular injection group 
(PAI). There was no  difference in length of stay. In view of the controversy over opioid use, 
we would  like to develop an optimal opioid sparing pain management approach by 
comparing  3 different protocol s 1) Plain local anesthetic EPCA; 2) PAI; 3) EPCA + PAI; all in  
conjunction with a multimodal opioid sparing pain regimen.  
2.0 OBJECTIVE OF CLINICAL STUDY  
The objective of this study is to maximize pain con trol while minimizing opioid use and side 
effects.  
3.0 STUDY HYPOTHESES  
Hypothesis 1:  Compare d to EPCA or PAI alone, the EPCA + PAI protocol will result  in: 
- lower opioid utilization  
- lower pain scores  
- lower opioid -related symptom distress scales  
- improved quality of recovery scores  
- higher patient satisfaction.  
Hypo thesis 2:  The use of EPCA + PAI pro tocol will lead to earlier “readiness for  discharge” 
to home or to a rehab facility compared to plain EPCA alone or PA I alone.  
4.0 STUDY DESIGN  
4.1 Endpoints  
4.1.1  Primary Endpoint  
• Opioid use (oral morphine equivalent s, cumulative, within 24 hours).  
4.1.2  Secondary Endpoints  
• Pain at rest via NRS scale (POD 1,2,3,  until D/C POD7 and 90)  
• Pain with physical therapy via NRS scale (POD 1,2,3,until D/C POD7 and 90)  
• Opioid side effects via ORSDS questionnaire (POD1,2)  
• Post-operativ e pain via Pain OUT questionnaire (POD 1)  
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 5 of 14 
 
• Patient sati sfaction (0 -10 Likert scale) regarding pain control (POD 1, 2, 3; POD7 &  
POD90)  
• Neuropathic pain via S -LANSS SF -8 (Pre -Op, POD 7 & 90)  
• Quality of Recovery via QoR -40 (POD 1,2,3)  
• Readiness for discharge time (At D/C)  
4.2 Study Sites  
This study will take place at the main campus of the Hospital for  Special Surgery.  
5.0 STUDY POPULATION  
5.1 Number of Subjects  
180 subjects (60 in each group).  
 
5.2 Inclusion Criteria  
Subjects of either gender will be included if : 
- Patients with osteoarthritis scheduled fo r primary total hip arthroplasty with 
participating surgeon  
- Age 45 to 80 years old  
- Planned use of regional anesthesia  
- Ability to follow study protocol  
- Planned posterolateral surgical approach  
 
5.3 Exclusion Criteria  
Subjects wil l be excluded from the study if : 
- Patients younger than 45 years old and older than 80  
- Patients intending to r eceive general anesthesia  
- Patients with an ASA of IV  
- Patients with insulin -dependent diabetes  
- Patients with hepatic (liver) failure (history of cir rhosis or elevated LFT’s)  
- Patients with chronic renal (kidney) failure (formal diagnosis of renal dis ease of  
elevated creatinine)  
- Chronic opioid use (taking opioids for longer than 3 months on a daily basis)  
- Patients with any prior major ipsilateral hip su rgery  
 
5.4 Randomization  
A block randomization scheme will be created by a statistician not involved with the  study. 
Prior to study start, 1) the randomization scheme will be shared with  pharmacy, and 2)  
sealed envelopes containing only the PAI portion of the  randomization assignments will be 
prepared by an unaffiliated RA and attached to  the study enrollment folders. When a patient 
is enrolled, pharmacy will be notified  and they will prepare the EPCA soluti on according to 
the randomization scheme.  The sealed e nvelope will be given to the physician who will open 
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 6 of 14 
 
it to reveal the PAI  portion of the randomization. This way the anesthesiologist and surgeon 
can remain blinded as to the EPCA (active vs. placebo) p ortion of the randomization.   
6.0 PROCEDURES  
6.1 Surgical Proc edure  
 
EPCA GROUP  
 
Pre-Operative Anes thesia/Analgesia  
• Baby ASA 81 mg  
• Cymbalta 60mg  
• Clonidine Patch 0.1mg for 24hr  
 
Opera ting Room  
• Anesthetic : Combined Spinal -Epidural with  1.5% Mepivacaine (4 cc), (if need to 
induce  hypotension, give Mepivacaine through  epidural). IV s edation with 
Midazolam,  Propofol (no opioids) *Ketamine 20 mg prior  to incision 30 mg in 
Propofol infusion  
• IV TXA 10 mg/kg up to 1000mg  
• Antiemetic : 20mg famotidine (Pepcid) and 4 mg ondansetron (Zofran) + *8 mg IV  
Decadron  
• *IV Tylenol prior to transfer to PACU  
• End of case: *Toradol (Ketorolac) (30 mg IV  if age 64 or younger, 15 mg IV if age 
>=65 or  weight <50 kg)  
 
Post -Operative Procedures  
• Foley catheter until POD 1 at  10:00 AM . Oral diet and physical  therapy upon block  
resolution.  
• Cymbalta 60 m g qd P OD1-2 
• PCEA (Bupivacaine 0.06%)  (4/4/10/20, initially).  
• Reduce PCA (0/4/10/20 POD1,  6:59). D/C PCA (POD1, 10:00)  
• Ondansetron (IV 4 mg q 8 hr  PRN)  
• Nalbuphine (IV 5 mg q 6 hr  PRN)  
• Continue IV Acetaminophen  (1000 mg q 6 hr for 3 doses  followed by oral do sing q 
6hr) 
• Toradol (30 mg IV q 6 hr until  POD 1, total 4 doses including  OR dose)  
• Oxycodone (5 mg q 3 hr PRN  for mild pain / 10 mg for  moderate to severe pain)  
• Celebrex 200 mg bid on POD 1  
• IV Pepcid 20 mg q 12 hr  
• Dilaudid (1 mg SQ q 4 hr PRN,  after PCA D/ C) 
• Remove Clonidine Patch 24  hours after application  
• Miralax 17g daily  
• ASA 325mg bid  
 
PAI GROUP  
 
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 7 of 14 
 
Pre-Operative Anesthesia/Analgesia  
• Baby ASA 81 mg  
• Cymbalta 60mg  
• Clonidine Patch 0.1mg for 24hr  
 
Operating Room  
• A. Anesthetic:  At end of surgery, the surgeon  performs a peri -articular injection.  
Protocolized method for injection.  *Deep Injection: (0.5% B upivacaine  with Epi, 30ml; 
morphine, 8 mg/ml, 1 ml; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 mg in 10 
ml; normal saline, 22ml). Superficial  injection: (4 0 ml 0.25% Bupivacaine).  
• B. Anesth etic: Combined Spinal -Epidural with  1.5% Mepivacaine (4 cc) (if neede d, 
can add lidocaine to epidural), (if  need to induce hypotension, give  Mepivacaine 
through epidural). IV  sedation with Midazolam, Propofol  (no opioids) *Ketamine 20 
mg prior to  incision 30 mg in Propofol infusion  
• IV TXA 10 mg/kg up to 1000mg  
• Antiemetic : 20mg famotidine (Pepcid) and 4 mg ondansetron (Zofran).*No Decadron  
because of steroids in injection.  
• *IV Tylenol 1000 mg prior to transfer to  PACU  
• End of case: *Toradol (Ketorolac) (30 mg I V if age 64 or younger, 15 mg IV if age 
>=65 or  weight <50 kg)  
 
Post -Opera tive Procedures  
• Foley catheter until POD 1 at  10:00 AM . Oral diet and physical  therapy upon block  
resolution.  
• Cymbalta 60 mg qd POD1 -2 
• Placebo epid ural pain pump  containing normal saline,  programmed as such:  
4/4/10/20, initially. Reduce PCA  (0/4/10/20 POD 1, 6:59). D/C  PCA (POD 1 10:00)   
• Ondansetron (IV 4 mg q 8 hr  PRN)  
• Nalbuphine (IV 5 mg q 6 hr  PRN).  
• Continue IV Acetaminophen  (1000 mg q 6 hr for 3 more  doses following oral dosing 
q 6 hr) 
• Toradol (30 mg q 6 hr u ntil POD  1, total 4 doses including OR  dose) 
• Oxycodone q 3 hr PRN (5 mg  for mild pain / 10 mg for  moderate to severe pain)  
• Celebrex 200 mg bid on POD 1  
• IV Pepcid 20 mg q 12hr  
• Dilaudid (1 mg SQ  q 4 hr PRN,  after PCA discontinuation)  
• Remove Clonidine Patch 2 4 hours after application  
• Miralax 17g daily  
• ASA 325 mg bid  
 
EPCA + PAI GROUP  
 
Pre-Operative Anesthesia/Analgesia  
• Baby ASA 81 mg  
• Cymbalta 60mg  
• Clonidine Patch 0.1mg for 24hr  
 
Operating Room  
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 8 of 14 
 
• Anesthetic : Combined Spinal -Epidural with  1.5% Mepivacaine (4 cc), (if need to 
induce  hypotension, give Mepivacaine through  epidural). IV sedation with 
Midazolam,  Propofol (no opioids) *Ketamine 20 mg prior  to incision 30 mg in 
Propofol infusion  
• IV TXA 10 mg/ kg up to 1000mg  
• Antiemetic : 20mg famotidine (Pepcid) and 4 mg ondansetron (Zofran)  
• *IV Tylenol prior to transfer to PACU  
• End of case : *Toradol ( Ketorolac) (30 mg IV  if age 64 or younger, 15 mg IV if age 
>=65 or  weight <50 kg)  
• *No Decadron given  
• C. At end of  surgery, the surgeon  performs a peri -articular injection.  Protocolized 
method for injection.  *Deep Injection: (0.5% Bupivacaine  with Epi, 30ml ; morphine, 8 
mg/ml, 1 ml; methylprednisolone, 40 mg/ml, 1 ml; cefazolin, 500 mg in 10 ml;  normal 
saline, 22ml). Su perficial  injection: (40 ml 0.25% Bupivacaine ). 
 
Post -Operative Procedures  
• Foley catheter until POD 1 at  10:00 AM . 3. Oral diet and physical  therapy upon block  
resolution.  
• Cymbalta 60 mg qd POD1 -2 
• PCEA (Bupivacaine 0.06%)  (4/4/10/20, initially).  
• Reduce PCA  (0/4/10/20 POD1,  6:59). D/C PCA (POD1, 10:00)  
• Ondansetron (IV 4 mg q 8 hr  PRN)  
• Nalbuphine (IV 5 mg q 6 hr  PRN)  
• Continue IV Acetaminophen  (1000 mg q 6 hr for 3 doses  followed by oral dosing q 
6hr) 
• Toradol (If age <=64, 30 mg IV  q 6 hr until POD 1, total 4  doses including OR dose) 
If age >=65 or weight <50kg, 15 mg 
• Oxycodone (5 mg q 3 hr PRN  for mild pain / 10 mg for  moderate to severe pain)  
• Celebrex 200 mg bid on POD 1  
• IV Pepcid 20 mg q 12 hr  
• Dilaudid (1 mg SQ q 4 hr PRN,  after PCA D/C)  
• Remove Clonidine Pat ch 24  hours after application  
• Miralax 17g daily  
• ASA 325mg bid  
 
6.2 Data Collection  
Data will be collected by an investigator or research assistant. Sources of data  include 
medical records and patient physical assessments/interviews  conducted by study personnel. 
Data will be recorded and managed using REDCap  electronic data capture tools hosted at 
the Clinical and Translational  Science Center (CTSC) at Weill Cornell Medical College. 
REDCap (Research  Electronic Data Capture) is a secure, web -based application designed 
to support  data capture for research studies, providing: 1) an intuitive i nterface for validated  
data entry; 2) audit trails for tracking data manipulation and export procedures; 3)  automated 
export procedures for seamless data downloads to common statistical  packages; and 4) 
procedures for importing data from external sources. Connection  to REDCap occurs via the 
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 9 of 14 
 
hospital’s encrypted cable and wireless networks, an d data will be entered through a 
password protected computer terminal or iPad.  
The following data will be collected:  
 
Pre-operative /Baseline  
• basic demographic data  
• patient weight & he ight, BMI  
• Comorbidities  
• NRS Pain score at rest a nd wi th activity  
• SF-8 Acute 
• S-LANSS  
 
POD 1  
• date of surgery  
• type of surgery  
• NRS pain score at rest and with activity  
• ORSDS  
• QoR-40 
• Pain outcomes questionnaire  
• Opioid dose  
• Patient Sat isfaction  
 
POD 2  
• NRS pain score at rest and with ac tivity 
• ORSDS  
• QoR-40 
• Opioid dose  
• Patient satisfaction  
 
POD 3 
• NRS pain score at rest and with ac tivity 
• QoR-40 
• Opioid dose  
• Patient satisfaction  
 
 
At Dischar ge 
• Blinding assessment  
 
 
POD 7 (Phone F/U)  
• NRS pain score at rest and with ac tivity 
• SF-8 Acute  
• S-LANSS  
• Blinding  Assessment  
• Opioid dose  
• Patient satisfaction  
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 10 of 14 
 
 
 
90 Days (Phone F/U)  
• NRS pain score at rest and with ac tivity 
• SF-8 Acute  
• S-LANSS  
• Opioid dose  
• Patient satisfaction  
Confidential  Page 11 of 14 
 
 6.3 Schedule of Assessments  
 
Procedures  Role  Day 
Before 
Surgery  Pre-Op POD1  POD2  POD3  At 
Discharge  POD 7  90 Day 
Phone 
F/U 
Eligibility Review  RA X        
Obtain Consent  Anes MD 
or RA   
X       
Demographics  RA  X       
Comorbidities  RA  X       
NRS Pain at res t/with acti vity RA  X X X X  X X 
SF-8 Acute  RA  X     X X 
S-LANSS  RA  X     X X 
ORSDS  RA   X X     
QoR -40 RA   X X X    
Pain Outcomes 
Questionnaire  RA   X      
Blinding Asses sment  RA      X X  
Opioid Dose  RA   X X X  X X 
Patient Satisfaction  RA   X X X  X X 
Confidential  Page 12 of 14 
 
 7.0 STATISTICAL ANALYSIS  
• Proposed analysis (e.g., student’s t -test, ANOVA, chisquare, regression, etc.):  
Independent two sample t -tests  
• Alpha level: 0.05/2 = 0.025. The primary goal of the study is to compare the  
combined intervention (EPCA+PAI) with EPCA alone and PAI alone. We ran a  
conservative power analysis for these two comparisons by  applying Bonferroni 
corrections. We assume tha t EPCA alone and PAI alone will  have similar effects. 
The comparison between these two groups is not the primary  interest of the study.  
• Beta or power level: 80%  
• Primary outcome variable estimate (mean +/s.d. for continuous outcome): Mean  ± 
SD opioid use (in 24hr)= 26 ± 22 mg OME  
• Number of groups being compared (use 1 for paired analysis within the same  
subjects): 2 (assuming that there is no difference betwe en EPCA alone and PAI  
alone).  
• Effect size or change expected between groups: Opioid use (in 24hr): 50%  reduction 
in OME  
• Sample size: We would need 60 patients per group to achieve 80% power for  
detecting the above effect size for opioid use. The sampl e size accounts for 10%  
missing observations due to withdraws, losses to follow up, etc.  
 
Continuous variables and discrete variables will be presented as mean+/ -sd and  proportion, 
respectively. Univariate analysis including t -test/Mann -Whitney  Wilcoxon Rank  test and Chi -
square/Fisher’s exact test will be conducted to  compare continuous and discrete outcomes 
(both primary and secondary) between  any two groups, respectively. Standard linear 
regression analysis can be used to  compare opioid use between the inte rvention groups  
 
8.0 ADVERSE EVENT ASSESSMENT  
All Adverse Events (AEs) will be reported in the final  study report. Definitions for Adverse 
Event (AE) used in this study are listed below and are based on FDA and international 
guidelines:  
 
8.1 Adverse Event Reporting  
We will have data safety board to check if patients in the study experience  increased pain, 
decreased quality of recovery and decreased satisfact ion with the  proposed regimens. The 
following physician s will be part of the safety board: Dr.  Kirksey, Dr. DelPizzo, Dr. 
Memtsoudis.   
Individual Stopping Criteria:  
The DSMB will review data related to the following individual stopping criteria:  
- Gastrointes tinal bleeding  
- Hematoma  
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 13 of 14 
 
- Blood in stool and/or vomit  
Incidences of these potential issues will be reported to the IRB using the SAE  
reporting form (attachment 3). The DSMB may recommend modification to  individual 
stopping rules if necessary and may recommen d stopping the study for  the following 
reasons:  
- The da ta show a significantly increased risk of serious adverse effects from  
the established incidence in the literature.  
- If any mortality is seen in study participants  
- All serious adverse events (SAE) will b e reported within 5 days of the 
occurrence to the DSMB  
 
9.0 REFERENCES  
1. Block BM, Liu SS, Rowlingson AJ, Cowan AR, Cowan JA Jr, Wu CL.  
Efficacy of Postoperative Epidural Analgesia: A Meta -analysis. JAMA  
2003;290:2455 -2463.  
2. Ranawat AS and Ranawat CS. Pain management and accelerated  
rehabilitation for total hip and total knee arthroplasty.J Arthroplasty  
2007;22:12 -15. 
3. Parvataneni HK, Shah VP, Howard H, Cole N, Ranawat AS, Ranawat CS.  
Controlling pain after total hip and knee arthroplasty using a multimodal  
protocol with local periarticular injections: A pr ospective randomized study. J  
Arthroplasty 2007;22:33 -8. 
4. Andersen KV, Pfeiffer -Jenses M, Haraldsted V, Soballe K. Reduced hospital  
stay and narcotic consumption, and improved mobilization with local and  
intraarticular infiltration after hip arthroplasty : a randomized clinical trial of an  
intraarticular technique versus epidural infusion in 80 patients. Acta Orthop  
2007;78:180 -6. 
5. JulesElysee KM, Goon AK, Westrich GH, Padgett DE, Mayman DJ,  
Ranawat AS, Ranawat CS, Lin Y, Kahn RL, Bhagat DD, Goytizolo EA, Ma Y,  
Reid SC, Curren J, YaDeau JT. PatientControlled Epidural Analgesia or  
Multimodal Pain Regimen with Periarticular Injectio n After Total Hip  
Arthroplasty. J Bone Joint Surg Am, May 2015; 97 (10): 789798  
6. Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes  
in pain severity. Ann Emerg Med 1996; 27(4): 485 –489 
7. Alam A, Gomes T, Zheng H, Mamdani MM, Juu rlink DN, Bell CM. Long -term 
analgesic use after low -risk surgery: a retrospective cohort study. Arch  
Intern Med. 2012 Mar 12;172(5):425 -30 
8. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on  
creatinine clearance in men: a cross -sectional and longitudinal study. J  
Gerontol 1976 Mar;31(2):155 -63. 
9. Vestergaard P , Rejnmark L, Mosekilde L. Fracture risk associated with the  
use of morphine and opiates. J Intern Med. 2006 Jul;260(1):76 -87. 
10. Dowell D, Haegerich TM, Chou R. CDC Guideline  for Prescribing Opioids for  
Chronic Pain --United States, 2016. JAMA. 2016 Apr 19;315(15):1624 -45. 
11. Clarke H, Soneji N, Ko DT, Yun L, Wijeysundera DN. Rates and risk factors  
for prolonged opioid use after major surgery: population based cohort study.  
BMJ. 2014 Feb 11;348:g1251.  
 Protocol Number: 2016 -0721  
Version Date: 06/25/2020  
 
Confidential  Page 14 of 14 
 
12. YaDeau JT, Brummett*CM, Mayman DJ, Lin Y, Goytizolo EA, Padgett DE,  
Alexiades MM, Kahn RL, Jules -Elysee KM, Westrich G, Gadulov Y, Fields  
KG, Goon AK,. Does Duloxetine Reduce Sub -Acute Pain After Knee  
Arthroplasty? A Randomize d Controlled Trial. Best of Meeting: American  
Society of Regional Anesthesia and Pain Medicine. Feb 23, 2015.  
13. Cuellar JM, Petrizzo A, Vaswani R, Goldstein, Bendo. Does Aspirin  
Administration Increase Perioperative Morbidity in Patients With Cardiac  
Stents Undergoing Spinal Surgery? Spine (Phila Pa 1976). 2015 May 1;40  
(9):629 -35. 
14. Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance  
or interruption of aspirin on thrombotic and bleeding events after elective  
non-cardiac surgery: the multicentre, randomized, blinded, placebocontrolled,  
STRATAGEM trial. Br J Anaesth 2011;107:899 –910 
15. Chechik O, Thein R, Fichman G, et al. The effect of  clopidogrel and aspirin  
on blood loss in hip fracture surgery. Injury 2011;42:1277 –82 
16. Morris T, Stables M, Hobbs A, de Souza P, Colville -Nash P, Warner T,  
Newson J, Bellingan G, Gilroy DW. Effects of Low -Dose Aspirin on Acute  
Inflammatory Responses in  Humans. J Immunol, 2009 Aug 1;183(3):2089 - 
96 
17. Aspirin in patients undergoing non -cardiac surgery. Devereaux PJ,  
Mrkobrada M, Sessler DI, Leslie K, Alonso -Coello P, Kurz A, Villar JC,  
Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A,  
Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M,  
Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom  
J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O,  
Srinathan S, Graham M, Pasin L, Le Manac h Y, Gao P, Pogue J, Whitlock R,  
Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S;  
POISE -2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1494 -50 